PsychedelicNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Delivers Improved Absorption and Application Versatility

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTECH™ enables improved bioabsorption and versatility in drug delivery applications. A recent article discussing the company’s unique technology reads: “DehydraTECH™ is a unique enabling technology from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) that increases the absorption rate of edible ingestion, delivering five to 10 times more of active ingredients than traditional edibles. This technology is not a competing technology but rather a complementary layer that provides a versatile range of commercial applications. LXRP is the only company in the world that has been awarded a patent for the improved (oral or ingestible) delivery of all non-psychoactive cannabinoids in the U.S. and Australia, and the company has 40 more patents pending worldwide. DehydraTECH™ is patented or patent pending for use with a broad range of bioactive molecules. There are many potential uses for this technology, which aims to enhance ingestible products in terms of taste, smell, speed of action, bioabsorption and bioavailability.”

To view the full article, visit http://cnw.fm/uYZu4

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. develops and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com

More from PsychedelicNewsBreaks

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050